The DNA sequencing company has secured a European injunction against a Chinese rival, while its largest early backer IP Group has trimmed its stake.
Oxford Nanopore Technologies (LSE:ONT) has been in the news on two fronts in recent weeks. In September, the FTSE 250 life sciences group won a preliminary injunction against a European Subsidiary of Chinese sequencing company MGI Tech, and on 2 October IP Group, one of its longest-standing shareholders, announced the sale of 10 million shares. Both developments come as the company works towards its target of reaching EBITDA breakeven next year.
Patent injunction against MGI
On 16 September, Oxford Nanopore said the Munich local division of the Unified Patent Court had granted it a preliminary injunction against MGI Tech GmbH. The order covers MGI's CycloneSEQ-WT02, CycloneSEQ-WY01, G100-ER and G400-ER systems and similar sequencers using materially the same technology, which Oxford Nanopore says infringe two of its European patents.
The injunction prevents MGI from making, selling, using, importing, storing or offering the systems and related flow cells in Denmark, France, Germany, the Netherlands, Liechtenstein, Switzerland, the UK and, in a more limited form, Ireland. It took effect immediately and is enforceable pending any appeal. Oxford Nanopore will seek a permanent injunction, with a full trial scheduled for October 2027. The company said its intellectual property is fundamental to the value it creates for customers, partners and shareholders.
IP Group trims its holding
On 2 October, IP Group said it had sold 10 million Oxford Nanopore shares, raising gross proceeds of around £21m, which implies a price of roughly 210p per share. IP Group continues to hold about 70.8 million shares, or 7.23% of the company, and has agreed a 90-day lock-up on its remaining direct stake. Funds managed by IP Group hold a further 11.8 million shares or so.
IP Group chief executive Greg Smith described Oxford Nanopore as one of the portfolio's standout successes and said the sale was a partial realisation that keeps meaningful exposure to future upside. Sales by a major holder can weigh on sentiment in the short term, but the lock-up limits the scope for further disposals from the direct holding in the near future.
Progress towards breakeven
The developments follow interim results in August that showed improving financial performance. For the six months to 30 June 2026, Revenue rose 10.5% to £116.7m, or 12.3% at constant currency. Clinical revenue grew 35.4% and biopharma revenue 25.0%, while the larger core segment grew 5.4%. Gross Margin improved by 400 basis points to 62.2%, and the adjusted EBITDA loss narrowed to £22.1m from £48.3m. Cash and liquid investments stood at £234.5m.
Regional performance was mixed. Revenue in Europe, the Middle East, Africa and India grew sharply, but Asia Pacific declined, with China down by about 16% at constant currency.
For 2026, the company expects constant-currency revenue growth of 16–20%, excluding a one-off licensing payment, and has narrowed guidance on operating cost growth to between a 2% fall and flat. It is targeting adjusted EBITDA breakeven in 2027 and positive free Cash Flow in 2028, with a 2030 ambition of more than $700m in revenue. Gross margin for the full year is expected to be around 62%, excluding the licensing revenue.
For FTSE 250 investors, Oxford Nanopore remains a growth-focused technology company where progress on profitability and the protection of its intellectual property are central to the Investment case. The next catalysts are likely to be any appeal by MGI and the company's full-year trading update.






Please wait processing your request...